SHR-2524

Unknown / undisclosed

Phase 1Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Hepatocellular Carcinoma
NCT07478302 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-04-14 – 2027-12 · Advanced Unresectable Hepatocellular Carcinoma
What this study did

Competitive landscape

This drug's own stage for Hepatocellular Carcinoma: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-2524: this drugPhase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4)
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1)
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signalNo reviewed efficacy summary in this indication
AmezalpatPhase 3Small moleculePPARα (peroxisome proliferator-activated receptor alpha)not yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 3Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NamodenosonPhase 3—Adenosine A3 receptornot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 3Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
PegargiminasePhase 3Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminasenot yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
RYZ801Phase 1/2Radiopharmaceutical—not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
SENTI-301APhase 1Cell therapyGPC3 (CAR-NK, calibrated IL-15)not yet gradedNo reviewed efficacy summary in this indication
AZD7003
—(overall)
Cell therapyGlypican-3 (GPC3)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-2524 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-10 · NCT07478302 · CT.gov ↗
What to watch

See the full readout calendar ↗